Digital In Vivo Alliance
Cary, NC
Dr. Brian Berridge is the Chair of the Digital In Vivo Alliance (DIVA) which is a collaboration of pharmaceutical scientists with a mutual interest in the development, validation, and application of AI-defined digital measures in animal studies that support drug discovery and development. He is also the Principal Consultant at B2 Pathology Solutions LLC, a consultancy practice that partners with global clients to support their efforts to translate their innovative products to preclinical or clinical impact.
At his retirement from the NIH in 2023, Brian was the Scientific Director of the Division of Translational Toxicology and Associate Director of the interagency National Toxicology Program at the National Institute of Environmental Health Sciences. Prior to that, he served as Head of Animal Research Strategy at GlaxoSmithKline. Brian is a veterinarian and board-certified as a veterinary pathologist. He received a PhD in Veterinary Pathology from Texas A&M University and spent 17 years in the pharmaceutical industry as a toxicologic pathologist with specialty expertise in cardiovascular pathology and translational animal research. He is the former Chair of the pharma industry’s IQ Consortium 3Rs Leadership Group where he also served as the Lead for the Microphysiological Systems Working Group. While at the NIH, he was a member of the NIH Advisory Committee to the Director’s Animal Research Rigor and Reproducibility Working Group. Brian is a member of the Advisory Committee to the Division of Earth and Life Studies at the National Academies and the Stakeholder Advisory Group for the EU’s Horizon 2020 Predictive Toxicology Project.
Opening General Session: More Cure, Less Side Effects: A Potential Role for Preclinical Studies
Wednesday, November 20, 2024
7:30 AM – 8:30 AM PT